Current Report Filing (8-k)
August 13 2019 - 4:06PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported):
August 12, 2019
CANCER
GENETICS, INC.
(Exact
Name of Registrant as Specified in its Charter)
Delaware
|
|
001-35817
|
|
04-3462475
|
(State
or Other Jurisdiction
|
|
(Commission
|
|
(IRS
Employer
|
of
Incorporation)
|
|
File
Number)
|
|
Identification
No.)
|
201
Route 17 North 2nd Floor, Rutherford, New Jersey
|
|
07070
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code
(201) 528-9200
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (
see
General Instruction A.2. below):
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined by Rule 405 of the Securities Act of 1933 (17 §230.405)
or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common
Stock
|
|
CGIX
|
|
The
Nasdaq Capital Market
|
Item
4.01. Changes in Registrant’s Certifying Accountant.
The
Audit Committee (the “Audit Committee”) of the Board of Directors of Cancer Genetics, Inc. (the “Company”)
has completed the process to identify and appoint a successor independent registered public accounting firm of the Company for
the fiscal year ending December 31, 2019. As a result of this process, on August 12, 2019, the Audit Committee engaged Marcum
LLP.
During
the Company’s fiscal years ended December 31, 2017 and 2018 and the subsequent interim period through August 12, 2019, neither
the Company nor anyone on its behalf has consulted with Marcum LLP on any matter that:
|
(i)
|
involved
the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion
that might be rendered on the Company’s financial statements, and neither a written report nor oral advice was provided
to the Company that Marcum LLP concluded was an important factor considered by the Company in reaching a decision as to any
accounting, auditing or financial reporting issue; or
|
|
(ii)
|
was
either the subject of a “disagreement” (as such term is defined in Item 304(a)(1)(iv) of Regulation S-K and the
related instructions to Item 304 of Regulation S-K) or a “reportable event” (as such term is defined in Item 304(a)(1)(v)
of Regulation S-K).
|
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
CANCER
GENETICS, INC.
|
|
|
|
|
By:
|
/s/
M. Glenn Miles
|
|
Name:
|
M.
Glenn Miles
|
|
Title:
|
Chief
Financial Officer
|
|
|
|
Date:
August 13, 2019
|
|
|
Cancer Genetics (NASDAQ:CGIX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cancer Genetics (NASDAQ:CGIX)
Historical Stock Chart
From Sep 2023 to Sep 2024